UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023885
Receipt number R000027512
Scientific Title Randomized controlled trial of the influence on mucosal regulatory T cells and fecal butyric acid by administration of Clostridium butyricum and resistant starch for pediatric ulcerative colitis
Date of disclosure of the study information 2016/09/01
Last modified on 2020/09/04 15:05:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized controlled trial of the influence on mucosal regulatory T cells and fecal butyric acid by administration of Clostridium butyricum and resistant starch for pediatric ulcerative colitis

Acronym

Randomized controlled trial of the influence on mucosal regulatory T cells and fecal butyric acid by administration of Clostridium butyricum and resistant starch for pediatric ulcerative colitis

Scientific Title

Randomized controlled trial of the influence on mucosal regulatory T cells and fecal butyric acid by administration of Clostridium butyricum and resistant starch for pediatric ulcerative colitis

Scientific Title:Acronym

Randomized controlled trial of the influence on mucosal regulatory T cells and fecal butyric acid by administration of Clostridium butyricum and resistant starch for pediatric ulcerative colitis

Region

Japan


Condition

Condition

Ulcerative colitis

Classification by specialty

Gastroenterology Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the frequency of relapse in pediatric ulcerative colitis patients, mucosal regulatry T cells and fecal butyric acid by the administration of Clostridium butyricum and resistant starch compared with conventional treatment.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the frequency of relapse in pediatric ulcerative colitis patients by the administration for 12 months.

Key secondary outcomes

mucosal regulatory T cells and fecal butyric acid by the administration for more than 1 month


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Food

Interventions/Control_1

Clostridium butyricum 3g of once, 3 times a day and resistant starch 10g of once, 2 times a day for 52 weeks.

Interventions/Control_2

Controls.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

8 years-old <=

Age-upper limit

19 years-old >

Gender

Male and Female

Key inclusion criteria

Pediatric ulcerative colitis patients aged from 8 year old to less than 19 year old with the agreement.

Key exclusion criteria

Patients with refusal for informed consent, and judged inappropriate.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Takahiro
Middle name
Last name Kudo

Organization

juntendo University Hospital

Division name

Department of Pediatrics and Adolescent Medicine

Zip code

113-8431

Address

3-1-3, Hongo, Bunkyo-ku, Tokyo, Japan

TEL

0338133111

Email

t-kudo@juntendo.ac.jp


Public contact

Name of contact person

1st name Takahiro
Middle name
Last name Kudo

Organization

juntendo University Hospital

Division name

Department of Pediatrics and Adolescent Medicine

Zip code

113-8431

Address

3-1-3, Hongo, Bunkyo-ku, Tokyo, Japan

TEL

0338133111

Homepage URL


Email

t-kudo@juntendo.ac.jp


Sponsor or person

Institute

juntendo University

Institute

Department

Personal name



Funding Source

Organization

juntendo University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

juntendo University Hospital

Address

3-1-3, Hongo, Bunkyo-ku, Tokyo, Japan

Tel

0338133111

Email

t-kudo@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

0

Results

The study was terminated because it did not lead to case enrollment and the study period ended.

Results date posted

2020 Year 09 Month 04 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 08 Month 25 Day

Date of IRB

2016 Year 07 Month 29 Day

Anticipated trial start date

2016 Year 09 Month 01 Day

Last follow-up date

2020 Year 07 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 09 Month 01 Day

Last modified on

2020 Year 09 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027512


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name